RSV infection without ribavirin treatment in pediatric hematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 51, Issue 10, 2016, Pages 1382-1384

  El Bietar, J ^a   Nelson, A ^a   Wallace, G ^a   Dandoy, C ^a   Jodele, S ^a   Myers, K C ^a   Teusink, A ^a   Lane, A ^a   Davies, S M ^a   Danziger Isakov, L ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIBAVIRIN;

CHILD; CONTROLLED STUDY; DISEASE SEVERITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFLUENZA A; INFLUENZA B; LETTER; LOWER RESPIRATORY TRACT INFECTION; LUNG CONGESTION; LUNG LAVAGE; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; NASOPHARYNGEAL SWAB; NOSE SMEAR; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; THORAX RADIOGRAPHY; THROAT CULTURE; UPPER RESPIRATORY TRACT INFECTION; ADOLESCENT; ADULT; ALLOTRANSPLANTATION; COHORT ANALYSIS; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; INFANT; MALE; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; INFANT; MALE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84968649844     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2016.124     Document Type: Letter

References (15)

1. El Saleeby CM, Somes GW, DeVincenzo JP, Gaur AH. Risk factors for severe respiratory syncytial virus disease in children with cancer: The importance of lymphopenia and young age. Pediatrics 2008; 121: 235-243.
2. Erard V, Chien JW, Kim HW, Nichols WG, Flowers ME, Martin PJ et al. Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: The role of community respiratory viruses. J Infect Dis 2006; 193: 1619-1625.
3. Boeckh M, Englund J, Li Y, Miller C, Cross A, Fernandez H et al. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis 2007; 44: 245-249.
4. Chemaly RF, Ghantoji SS, Shah DP, Shah JN, El Taoum KK, Champlin RE et al. Respiratory syncytial virus infections in children with cancer. J Pediatr Hematol Oncol 2014; 36: e376-381.
5. Chemaly RF, Torres HA, Munsell MF, Shah DP, Rathod DB, Bodey GP et al. An adaptive randomized trial of an intermittent dosing schedule of aerosolized ribavirin in patients with cancer and respiratory syncytial virus infection. J Infect Dis 2012; 206: 1367-1371.
6. Shah DP, Ghantoji SS, Shah JN, El Taoum KK, Jiang Y, Popat U et al. Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother 2013; 68: 1872-1880.
7. Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood 2011; 117: 2755-2763.
8. Schiffer JT, Kirby K, Sandmaier B, Storb R, Corey L, Boeckh M. Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation. Haematologica 2009; 94: 1101-1108.
9. Seo S, Campbell AP, Xie H, Chien JW, Leisenring WM, Englund JA et al. Outcome of respiratory syncytial virus lower respiratory tract disease in hematopoietic cell transplant recipients receiving aerosolized ribavirin: significance of stem cell source and oxygen requirement. Biol Blood Marrow Transplant 2013; 19: 589-596.
10. Matejtschuk P, Chidwick K, Prince A, More JE, Goldblatt D. A direct comparison of the antigen-specific antibody profiles of intravenous immunoglobulins derived from US and UK donor plasma. Vox Sang 2002; 83: 17-22.
11. Committee on Infectious D. From the American Academy of Pediatrics: Policy statements-Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009; 124: 1694-1701.
12. Kassis C, Champlin RE, Hachem RY, Hosing C, Tarrand JJ, Perego CA et al. Detection and control of a nosocomial respiratory syncytial virus outbreak in a stem cell transplantation unit: The role of palivizumab. Biol Blood Marrow Transplant 2010; 16: 1265-1271.
13. de Fontbrune FS, Robin M, Porcher R, Scieux C, de Latour RP, Ferry C et al. Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2007; 45: 1019-1024.
14. Adams R, Christenson J, Petersen F, Beatty P. Pre-emptive use of aerosolized ribavirin in the treatment of asymptomatic pediatric marrow transplant patients testing positive for RSV. Bone Marrow Transplant 1999; 24: 661-664.
15. Chavez-Bueno S, Mejias A, Merryman RA, Ahmad N, Jafri HS, Ramilo O. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients. Pediatr Infect Dis J 2007; 26: 1089-1093.